Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 11/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117725 | 0.81 | GHSR (0.41) | PIK3CBALDH1A1CYP2C9KMT2A | |
| SCHEMBL2119312 | 0.74 | ALPL (0.40) | ALPLLMNA | |
| SCHEMBL2118607 | 0.72 | FFAR4 (0.54) | PIK3CBALDH1A1SYKLMNASMN1; SMN2 | |
| SCHEMBL2118551 | 0.71 | PIK3CB (0.50) | PIK3CBALDH1A1SYKLMNATP53 | |
| SCHEMBL2119745 | 0.69 | FFAR4 (0.64) | ALDH1A1SYKLMNA | |
| SCHEMBL2117419 | 0.68 | USP2 (0.42) | ALDH1A1CYP2C9KMT2ATP53 | |
| SCHEMBL2118247 | 0.68 | ALPL (0.54) | ALPLALDH1A1SYKKMT2ALMNA | |
| SCHEMBL2118403 | 0.68 | FFAR4 (0.54) | PIK3CBALDH1A1SYKLMNAHPGD | |
| SCHEMBL2118102 | 0.67 | PIK3CB (0.41) | PIK3CBALPLALDH1A1SYKLMNA | |
| SCHEMBL2117686 | 0.67 | FFAR4 (0.61) | ALDH1A1SYKLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | PIK3CB 1820/4885ALPL 3436/4885ALDH1A1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.